Key Developments

  • GSK’s bepirovirsen met primary goals in two Phase 3 studies targeting chronic hepatitis B.
  • The therapy achieved functional cure rates after six months of treatment.
  • This antisense oligonucleotide approach could replace long-term antiviral therapies that patients currently must take indefinitely.

Implications

  • Functional cure represents a significant clinical milestone, potentially reducing the disease burden and improving patient outcomes.
  • This advancement positions GSK competitively within liver infectious disease therapeutics.

Context

Chronic hepatitis B affects millions worldwide, and current treatments mainly suppress viral replication without cure. A finite, functionally curative therapy could transform patient management and global health impact.

Source: medcitynews.com